2022
PD10-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM FOLLOW-UP RESULTS FROM THE JAVELIN BLADDER 100 TRIAL
Grivas P, Bellmunt J, Park H, Voog E, Caserta C, Valderrama B, Gurney H, Loriot Y, Sridhar S, Tsuchiya N, Sternberg C, Aragon-Ching J, Petrylak D, Blake-Haskins J, Laliberte R, Wang J, Costa N, Powles T. PD10-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM FOLLOW-UP RESULTS FROM THE JAVELIN BLADDER 100 TRIAL. Journal Of Urology 2022, 207: e183. DOI: 10.1097/ju.0000000000002536.02.Peer-Reviewed Original Research
2021
698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Sridhar S, Pappot H, Gurney H, Bedke J, van der Heijden M, Campbell M, Wu C, Matsangou M, Petrylak D. 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma. Annals Of Oncology 2021, 32: s710-s711. DOI: 10.1016/j.annonc.2021.08.094.Peer-Reviewed Original Research
2019
SC170 Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): The ARCHES trial
Basso U, Galetti T, Armstrong A, Szmulewitz R, Petrylak D, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore N, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. SC170 Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): The ARCHES trial. European Urology Open Science 2019, 18: e3258. DOI: 10.1016/s1569-9056(19)33650-4.Peer-Reviewed Original ResearchPT126 A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress
Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A, Powles T. PT126 A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress. European Urology Open Science 2019, 18: e1836-e1837. DOI: 10.1016/s1569-9056(19)31330-2.Peer-Reviewed Original Research
2016
780PD Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)
Petrylak D, Heath E, Sonpavde G, George S, Morgans A, Eigl B, Picus J, Cheng S, Hotte S, Gartner E, Vincent M, Chu R, Anand B, Morrison K, Jackson L, Melhem-Bertrandt A, Yu E. 780PD Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC). Annals Of Oncology 2016, 27: vi269. DOI: 10.1093/annonc/mdw373.08.Peer-Reviewed Original Research842TiP A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
Powles T, Grivas P, Aragon-Ching J, Faroun Y, Kessler E, Tomita Y, Chakrabarti D, Laliberte R, Shnaidman M, Petrylak D. 842TiP A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). Annals Of Oncology 2016, 27: vi292. DOI: 10.1093/annonc/mdw373.69.Peer-Reviewed Original Research788P Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)
Rosenberg J, Heath E, Perez R, Merchan J, Lang J, Ruether D, Petrylak D, Sangha R, Smith D, Sridhar S, Gartner E, Vincent M, Chu R, Anand B, Donate F, Melhem-Bertrandt A, Zhang J. 788P Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC). Annals Of Oncology 2016, 27: vi273. DOI: 10.1093/annonc/mdw373.16.Peer-Reviewed Original ResearchAnti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
Petrylak D, Heath E, Sonpavde G, George S, Morgans A, Eigl B, Picus J, Cheng S, Hotte S, Gartner E, Vincent M, Chu R, Anand B, Morrison K, Jackson L, Reyno L, Yu E. Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2016, 34: 4532-4532. DOI: 10.1200/jco.2016.34.15_suppl.4532.Peer-Reviewed Original ResearchAnti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
Rosenberg J, Heath E, Van Veldhuizen P, Merchan J, Lang J, Ruether J, Petrylak D, Sangha R, Smith D, Sridhar S, Gartner E, Vincent M, Chu R, Anand B, Donate F, Jackson L, Reyno L, Zhang J. Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2016, 34: 4533-4533. DOI: 10.1200/jco.2016.34.15_suppl.4533.Peer-Reviewed Original Research
2015
419 Androgen receptor (AR) and AR-V7 expression in circulating tumor cells (CTCs) and response to prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in castration-resistant prostate cancer: A correlative analysis from a phase 2 trial
Petrylak D, DiPippo V, Werner S, Baird S, Anderson A, Marrinucci D, Israel R. 419 Androgen receptor (AR) and AR-V7 expression in circulating tumor cells (CTCs) and response to prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in castration-resistant prostate cancer: A correlative analysis from a phase 2 trial. European Journal Of Cancer 2015, 51: s84-s85. DOI: 10.1016/s0959-8049(16)30253-2.Peer-Reviewed Original Research2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo
Petrylak D, Eigl B, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar S, Sternberg C, Retz M, Blumenstein B, Jacobs C, Stewart P, Bellmunt J. 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo. European Journal Of Cancer 2015, 51: s525. DOI: 10.1016/s0959-8049(16)31454-x.Peer-Reviewed Original ResearchFirst-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.
Bellmunt J, Eigl B, Senkus-Konefka E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar S, Sternberg C, Retz M, Blumenstein B, Jacobs C, Stewart P, Petrylak D. First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. Journal Of Clinical Oncology 2015, 33: 4503-4503. DOI: 10.1200/jco.2015.33.15_suppl.4503.Peer-Reviewed Original Research
2014
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
Petrylak D, Smith D, Appleman L, Fleming M, Hussain A, Dreicer R, Sartor A, Shore N, Vogelzang N, Youssoufian H, DiPippo V, Stambler N, Huang K, Israel R. A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2014, 32: 5023-5023. DOI: 10.1200/jco.2014.32.15_suppl.5023.Peer-Reviewed Original ResearchThe site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.
Halabi S, Kelly W, Zhou H, Armstrong A, Quinn D, Fizazi K, Solomon N, Tannock I, Petrylak D, Morris M, Small E. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. Journal Of Clinical Oncology 2014, 32: 5002-5002. DOI: 10.1200/jco.2014.32.15_suppl.5002.Peer-Reviewed Original ResearchMP70-20 A PHASE 2 TRIAL OF PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN TAXANE-TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Petrylak D, Smith D, Appleman L, Fleming M, Hussain A, Dreicer R, Sartor A, Shore N, Vogelzang N, Youssoufian H, Olson W, Stambler N, Huang K, Israel R. MP70-20 A PHASE 2 TRIAL OF PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN TAXANE-TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). Journal Of Urology 2014, 191: e813-e814. DOI: 10.1016/j.juro.2014.02.2218.Peer-Reviewed Original Research870 A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (MCRPC)
Petrylak D, Smith D, Appleman L, Fleming M, Hussain A, Dreicer R, Sartor O, Shore N, Vogelzang N, Youssoufian H, Stambler N, Huang K, Israel R. 870 A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (MCRPC). European Urology Open Science 2014, 13: e870. DOI: 10.1016/s1569-9056(14)60857-5.Peer-Reviewed Original Research
2012
244 Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
Petrylak D, Kantoff P, Mega A, Stephenson J, Vogelzang N, Fleming M, Blattman S, Stambler N, D'Ambrosio P, Israel R. 244 Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC). European Journal Of Cancer 2012, 48: 75. DOI: 10.1016/s0959-8049(12)72042-7.Peer-Reviewed Original Research1666 SWOG S0353 PHASE II TRIAL OF INTRAVESICAL GEMCITABINE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER WHO RECURRED FOLLOWING AT LEAST TWO PRIOR COURSES OF BCG
Skinner E, Goldman B, Sakr W, Petrylak D, Lenz H, Lee C, Wilson S, Lerner S, Tangen C, Thompson I. 1666 SWOG S0353 PHASE II TRIAL OF INTRAVESICAL GEMCITABINE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER WHO RECURRED FOLLOWING AT LEAST TWO PRIOR COURSES OF BCG. Journal Of Urology 2012, 187: e673. DOI: 10.1016/j.juro.2012.02.1524.Peer-Reviewed Original Research123 Time to disease-related pain (TDRP) following sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Integrated results from three randomized phase 3 trials
Small E, Higano C, Kantoff P, Whitmore J, Frohlich M, Petrylak D. 123 Time to disease-related pain (TDRP) following sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Integrated results from three randomized phase 3 trials. European Urology Open Science 2012, 11: e123-e123a. DOI: 10.1016/s1569-9056(12)60122-5.Peer-Reviewed Original Research
2011
MP-16.01 Cellular and Humoral Immune System Activation by Sipuleucel-T: Preliminary Data from the OpenACT Phase 2 Trial
Petrylak D, Corman J, Hall S, Nabhan C, Ferrari A, Armstrong A, Dawson N, Sims R, Stewart F, Sheikh N. MP-16.01 Cellular and Humoral Immune System Activation by Sipuleucel-T: Preliminary Data from the OpenACT Phase 2 Trial. Urology 2011, 78: s147. DOI: 10.1016/j.urology.2011.07.369.Peer-Reviewed Original Research